HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $13.60, but opened at $14.38. HUTCHMED shares last traded at $14.18, with a volume of 39,504 shares changing hands.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on HCM. HSBC lowered shares of HUTCHMED from a "buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Wall Street Zen downgraded shares of HUTCHMED from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 22nd.
Read Our Latest Stock Analysis on HCM
HUTCHMED Stock Performance
The firm has a 50 day moving average price of $14.06 and a 200-day moving average price of $14.82. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07.
Hedge Funds Weigh In On HUTCHMED
Several large investors have recently bought and sold shares of the stock. Jane Street Group LLC lifted its position in HUTCHMED by 128.0% during the 1st quarter. Jane Street Group LLC now owns 222,241 shares of the company's stock worth $3,343,000 after acquiring an additional 124,771 shares during the period. Goldman Sachs Group Inc. raised its position in shares of HUTCHMED by 8.5% in the first quarter. Goldman Sachs Group Inc. now owns 93,919 shares of the company's stock valued at $1,413,000 after buying an additional 7,342 shares during the last quarter. Vident Advisory LLC lifted its stake in shares of HUTCHMED by 78.3% during the first quarter. Vident Advisory LLC now owns 19,728 shares of the company's stock valued at $297,000 after buying an additional 8,664 shares during the period. XY Capital Ltd boosted its position in HUTCHMED by 142.4% during the first quarter. XY Capital Ltd now owns 113,136 shares of the company's stock worth $1,702,000 after acquiring an additional 66,460 shares during the last quarter. Finally, Crossmark Global Holdings Inc. boosted its position in HUTCHMED by 31.4% during the first quarter. Crossmark Global Holdings Inc. now owns 24,420 shares of the company's stock worth $367,000 after acquiring an additional 5,829 shares during the last quarter. Institutional investors and hedge funds own 8.82% of the company's stock.
About HUTCHMED
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Read More
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
